A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Inclusion Criteria:

• - Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit
• Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion Criteria:

• Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
• Other exclusions applied